Cargando…

2648. Terminating the Troll of Transplantation: Letermovir for Cytomegalovirus Prophylaxis

BACKGROUND: Letermovir is a novel antiviral that was approved for cytomegalovirus (CMV) prophylaxis after allogeneic hematopoietic stem cell transplant (allo-HSCT). The objective was to assess the real-world outcomes of CMV prophylaxis with letermovir compared with preemptive therapy (PT) alone. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hedvat, Jason, Lake, Patrick, Swamy, Siddharth, Zecchini, Julia, Pereiras, Maribel, Sebti, Rani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810011/ http://dx.doi.org/10.1093/ofid/ofz360.2326

Ejemplares similares

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults
por: Politikos, Ioannis, et al.
Publicado: (2022)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
por: Martino, Massimo, et al.
Publicado: (2021)

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients
por: Körholz, Katharina F., et al.
Publicado: (2022)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Wolfe, Delaney, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Letermovir for the compassionate therapeutic use of cytomegalovirus infection
por: Schubert, Lorenz, et al.
Publicado: (2020)

Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data
por: Derigs, Patrick, et al.
Publicado: (2020)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
por: El Helou, Guy, et al.
Publicado: (2019)

2740. Letermovir for the Prevention and Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
por: Xhemali, Xhilda, et al.
Publicado: (2023)

Cytomegalovirus: A Troll in the ICU? Overview of the Literature and Perspectives for the Future
por: Schildermans, Jolien, et al.
Publicado: (2020)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
por: Sepassi, Aryana, et al.
Publicado: (2023)

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting
por: Marzolini, Maria A. V., et al.
Publicado: (2021)

Haters Gonna Hate, Trolls Gonna Troll: The Personality Profile of a Facebook Troll
por: Gylfason, Haukur Freyr, et al.
Publicado: (2021)

571. “Real world” Impact of Letermovir for Prevention of Cytomegalovirus Infection in Hematopoietic-Cell Transplantation
por: Loecher, Alyssa M, et al.
Publicado: (2020)

Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients
por: Santos Bravo, Marta, et al.
Publicado: (2022)

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

In vitro assessment of the combined effect of letermovir and sirolimus on cytomegalovirus replication
por: Giménez, Estela, et al.
Publicado: (2023)

The mouse that trolled
por: Hardy, John
Publicado: (2015)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial
por: Golan, Yoav, et al.
Publicado: (2021)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
por: Nho, Dukhee, et al.
Publicado: (2023)

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
por: Shigle, Terri Lynn, et al.
Publicado: (2020)

Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
por: Popping, Stephanie, et al.
Publicado: (2019)

To troll or not to troll: Young adults’ anti-social behaviour on social media
por: Soares, Felipe Bonow, et al.
Publicado: (2023)

The mouse that trolled (again)
por: Cook-Deegan, Robert, et al.
Publicado: (2016)

Trash-Talking and Trolling
por: Kniffin, Kevin M., et al.
Publicado: (2018)

Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies
por: Vyas, Ami, et al.
Publicado: (2022)

Troll story: The dark tetrad and online trolling revisited with a glance at humor
por: Volkmer, Sara Alida, et al.
Publicado: (2023)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
por: Royston, Léna, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Royston, Léna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mm0p37dubva96cvmjahj7udl1f